There is a question underneath every price comparison on this site, and it is not which seller is cheapest. It is whether the drug is worth its price at all. Health economists have a formal way of answering that, and a 2024 systematic review pooled seven studies that had done so [1]. The answer is genuinely split, and the split runs along a line most buyers never consider — and it is a different question from which seller is cheapest.
What the review found
Semaglutide produced more quality-adjusted life years than the comparator anti-obesity drugs — phentermine-topiramate, phentermine, and naltrexone-bupropion — and it cost more, with the incremental cost-effectiveness ratio exceeding the willingness-to-pay threshold in some cases. Against diet and exercise, and against liraglutide, it came out cost-effective. Against sleeve gastrectomy, endoscopic sleeve gastroplasty and gastric bypass, it did not.
The modeled lifetime costs in class I obesity (BMI 33) give the shape of it: lifestyle intervention at $124,195, endoscopic sleeve gastroplasty at $126,732, sleeve gastrectomy at $139,971, and semaglutide at $370,776.
The number the review does not give
A systematic review pools conclusions rather than ratios, so it is worth reading one of the underlying models directly. A 30-year Markov model from a US third-party payer perspective estimated that semaglutide 2.4 mg improved QALYs by 0.138 to 0.925 against its comparators while costing $3,254 to $25,086 more, putting the incremental cost at $23,556 to $144,296 per QALY gained [2]. Against a willingness-to-pay threshold of $150,000 per QALY, that is cost-effective against every comparator it tested — and the top of the range clears the bar by under six thousand dollars.
Two caveats belong with it. The model’s own sensitivity analysis identified treatment duration, what happens after discontinuation, and weight-rebound rates as the key drivers of the result, which is to say the answer depends most on the things nobody can promise. And the study was funded by Novo Nordisk, two of its authors were employees of the company, and the sponsor was involved in the study design, the interpretation of the data, the writing and the decision to submit. That does not make the arithmetic wrong; it means the reader should know whose model it is.
Why surgery wins on this measure and not on every measure
A bariatric operation is a large cost once. A GLP-1 is a smaller cost indefinitely, and indefinitely is the word doing the work — a drug taken for life accumulates past a one-time procedure at some point, and these models find that point. That is an argument about money over decades, not about which is right for a particular person, and it says nothing about risk, recovery, reversibility or preference.
It does have one practical implication for anyone reading a seller’s page: the cost-effectiveness case for this drug class rests on continuing to take it, while roughly one in three people are still on therapy at a year. A course that stops early carries the cost without the modeled benefit.
What this changes at the checkout
Two things. First, the spread between sellers is not noise at this scale — published semaglutide figures on this market run from $69 to $449 a month across 432 sellers, which over a multi-year course is a difference measured in tens of thousands of dollars, and the full distribution shows where any quote sits in it. Second, a headline that is not the billed figure compounds over that same horizon, and a large share of this market publishes one.
If the decision is close, the comparison worth running is not one seller against another but the whole course against the alternatives — which is a conversation for a clinician rather than a price page. The cost calculator will at least put a real number on the drug half of it.
Price figures are computed from this site’s own records at build time, most recently read September 2026. The economic figures are cited and are modeled, not observed.